rye-va-STIG-meen 
PO:
Transdermal:
Contraindicated in:
Use Cautiously in:
CV: HF, edema, hypotension.
Derm: allergic dermatitis.
GI: anorexia, diarrhea, nausea, vomiting, ↓ weight, abdominal pain, dyspepsia, flatulence.
Local: application reactions (for transdermal patch only).
Neuro: weakness, dizziness, drowsiness, headache, tremor.
Misc: fever.
(Generic available)
Hepatic Impairment
Therapeutic Classification: anti-Alzheimers's agents
Pharmacologic Classification: cholinergics (cholinesterase inhibitors)
Absorption: Well absorbed following oral administration. Transdermal patch is slowly absorbed over 8 hr.
Distribution: Widely distributed to tissues.
Metabolism/Excretion: Rapidly and extensively metabolized by the liver; metabolites are excreted by the kidneys.
Half-life: PO: 1.5 hr; Transdermal: 24 hr.
(improvement in dementia)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 2 wk | up to 12 wk | unknown |
| Transdermal | unknown | unknown | unknown |
NDC Code*